Chemotherapy-induced Nausea and Vomiting

7
Pipeline Programs
4
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Heron Therapeutics
2 programs
1
1
APF530Phase 31 trial
GRANISETRON EXTENDED RELEASE INJECTIONPhase 21 trial
Active Trials
NCT04085393WithdrawnEst. Dec 2022
NCT02106494CompletedEst. May 2015
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLM2010 for injection；dexamethasonePhase 31 trial
Active Trials
NCT07081256CompletedEst. Oct 2025
M&
Merck & Co.RAHWAY, NJ
4 programs
3
1
FosaprepitantPhase 21 trial
90 mg MK-0517Phase 11 trial
Comparator: Treatment APhase 11 trial
ondansetron clinical trial formulationPhase 11 trial
Active Trials
NCT00990821Completed188Est. Jan 2006
NCT00971633Completed12Est. Jan 2004
NCT00972595Completed45Est. Sep 2004
+1 more trials
Otolith Labs
Otolith LabsDC - Washington
1 program
OtobandN/A1 trial
Active Trials
NCT03996863WithdrawnEst. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalQLM2010 for injection；dexamethasone
Heron TherapeuticsAPF530
Heron TherapeuticsGRANISETRON EXTENDED RELEASE INJECTION
Merck & Co.Fosaprepitant
Merck & Co.90 mg MK-0517
Merck & Co.ondansetron clinical trial formulation
Merck & Co.Comparator: Treatment A
Otolith LabsOtoband

Clinical Trials (8)

Total enrollment: 258 patients across 8 trials

NCT07081256Qilu PharmaceuticalQLM2010 for injection；dexamethasone

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Start: Jan 2025Est. completion: Oct 2025
Phase 3Completed
NCT02106494Heron TherapeuticsAPF530

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Start: Mar 2014Est. completion: May 2015
Phase 3Completed
NCT04085393Heron TherapeuticsGRANISETRON EXTENDED RELEASE INJECTION

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

Start: Aug 2020Est. completion: Dec 2022
Phase 2Withdrawn
NCT01874119Merck & Co.Fosaprepitant

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Start: Sep 2013Est. completion: Dec 201513 patients
Phase 2Terminated
NCT00990821Merck & Co.90 mg MK-0517

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Start: Jan 2005Est. completion: Jan 2006188 patients
Phase 1Completed
NCT00972595Merck & Co.ondansetron clinical trial formulation

Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

Start: Jun 2004Est. completion: Sep 200445 patients
Phase 1Completed
NCT00971633Merck & Co.Comparator: Treatment A

A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

Start: Nov 2003Est. completion: Jan 200412 patients
Phase 1Completed
NCT03996863Otolith LabsOtoband

Prevention of Unmitigated Chemotherapy-induced Emesis

Start: Aug 2019Est. completion: Aug 2019
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space